Chester County News and Community Website
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that …
Read More The U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to …
Read More
HARRISBURG, PA — The Pennsylvania Department of Health approved the eighth clinical registrant, Goodblend Pennsylvania, LLC, who will be part of the state’s first-in-the-nation research program for medical marijuana. A …
Read More
EXTON, PA — Immunome, a biotechnology company that harnesses the human B cell response to develop first-in-class therapeutics for oncology and infectious diseases, recently announced it has been awarded up …
Read More
MALVERN, PA — Venatorx Pharmaceuticals announced recently that it has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department …
Read More
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced a virtual poster presentation highlighting new Phase IIIb ANJESO® (meloxicam) injection …
Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) announced that 200,000 patients have been treated with the minimally invasive UroLift® System for benign prostatic hyperplasia (BPH) worldwide.
Read More
MALVERN, PA — XyloCor Therapeutics recently announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and …
Read More
The U.S. Food and Drug Administration reissued the LabCorp COVID-19 RT-PCR Test emergency use authorization (EUA) to include two new indications for use: testing for people who do not have …
Read More
The U.S. Food and Drug Administration recently approved Tecartus (brexucabtagene autoleucel), a cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded …
Read More